Development of glaucoma drug insert progresses

ForSight Vision5, Inc., announced that it has raised $15 million in its latest funding round and completed enrollment in its phase 2 clinical study for the Helios ocular insert, its lead product candidate.

Helios is a noninvasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive medication. The company is developing noninvasive products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye and allergy.

“The company's lead product candidate has the potential to change how we treat patients who have glaucoma and ocular hypertension; in the longer term, the company's Helios platform may provide an alternative method to treat our patients across a broader spectrum of chronic eye disease,” said James Brandt, professor at the University of California, Davis and the study’s principal investigator.